Literature DB >> 28803400

Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.

Jeremy Cypen1, Tariq Ahmad2, Jeffrey M Testani2, Adam D DeVore3,4.   

Abstract

PURPOSE OF REVIEW: The use of biomarkers in heart failure (HF) is a rapidly changing field. The purpose of this review is to assess the current evidence of the use of biomarkers for risk stratification in patients with HF with preserved ejection fraction (HFpEF). RECENT
FINDINGS: Despite differences in pathophysiology between HF with reduced ejection fraction and HFpEF, traditional HF biomarkers such as brain natriuretic peptide and troponin retain prognostic value in most HFpEF-specific populations. Biomarkers of key pathophysiologic components of HFpEF, such as myocardial fibrosis, remodeling, and systemic inflammation are also valuable prognostic markers. Further investigation into HF biomarkers may identify significant therapeutic targets for the treatment of HFpEF.

Entities:  

Keywords:  Biomarkers; Heart failure; Prognosis; Risk stratification

Mesh:

Substances:

Year:  2017        PMID: 28803400     DOI: 10.1007/s11897-017-0358-4

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  85 in total

1.  2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  Circulation       Date:  2016-05-20       Impact factor: 29.690

Review 2.  Adrenomedullin--physiological regulator of the cardiovascular system or biochemical curiosity?

Authors:  K Kitamura; T Eto
Journal:  Curr Opin Nephrol Hypertens       Date:  1997-01       Impact factor: 2.894

3.  Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate.

Authors:  Kevin Damman; Dirk J Van Veldhuisen; Gerjan Navis; Vishal S Vaidya; Tom D J Smilde; B Daan Westenbrink; Joseph V Bonventre; Adriaan A Voors; Hans L Hillege
Journal:  Heart       Date:  2010-08       Impact factor: 5.994

4.  Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.

Authors:  Stanislava Zabarovskaja; Camilla Hage; Cecilia Linde; Jean-Claude Daubert; Erwan Donal; Anders Gabrielsen; Linda Mellbin; Lars H Lund
Journal:  Int J Cardiol       Date:  2015-03-27       Impact factor: 4.164

5.  Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.

Authors:  Tibor Kempf; Stephan von Haehling; Timo Peter; Tim Allhoff; Mariantonietta Cicoira; Wolfram Doehner; Piotr Ponikowski; Gerasimos S Filippatos; Piotr Rozentryt; Helmut Drexler; Stefan D Anker; Kai C Wollert
Journal:  J Am Coll Cardiol       Date:  2007-08-24       Impact factor: 24.094

Review 6.  Growth differentiation factor 15 in heart failure: an update.

Authors:  Kai C Wollert; Tibor Kempf
Journal:  Curr Heart Fail Rep       Date:  2012-12

7.  Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.

Authors:  Dirk J Lok; Ijsbrand T Klip; Adriaan A Voors; Sjoukje I Lok; Pieta W Bruggink-André de la Porte; Hans L Hillege; Tiny Jaarsma; Dirk J van Veldhuisen; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2014-07-31       Impact factor: 15.534

8.  Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

Authors:  A Rogier van der Velde; Lars Gullestad; Thor Ueland; Pål Aukrust; Yu Guo; Aram Adourian; Pieter Muntendam; Dirk J van Veldhuisen; Rudolf A de Boer
Journal:  Circ Heart Fail       Date:  2013-02-08       Impact factor: 8.790

9.  Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.

Authors:  Rajalakshmi Santhanakrishnan; Jenny P C Chong; Tze P Ng; Lieng H Ling; David Sim; Kui Toh G Leong; Poh Shuan D Yeo; Hean Y Ong; Fazlur Jaufeerally; Raymond Wong; Ping Chai; Adrian F Low; Arthur Mark Richards; Carolyn S P Lam
Journal:  Eur J Heart Fail       Date:  2012-08-05       Impact factor: 15.534

10.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.

Authors:  Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen
Journal:  Ann Med       Date:  2010-12-28       Impact factor: 4.709

View more
  7 in total

1.  Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients.

Authors:  Cho-Kai Wu; Mao-Yuan M Su; Yi-Fan Wu; Juey-Jen Hwang; Lian-Yu Lin
Journal:  J Clin Med       Date:  2018-11-08       Impact factor: 4.241

2.  Improving risk stratification in heart failure with preserved ejection fraction by combining two validated risk scores.

Authors:  Kalyani Anil Boralkar; Yukari Kobayashi; Kegan J Moneghetti; Vedant S Pargaonkar; Mirela Tuzovic; Gomathi Krishnan; Matthew T Wheeler; Dipanjan Banerjee; Tatiana Kuznetsova; Benjamin D Horne; Kirk U Knowlton; Paul A Heidenreich; Francois Haddad
Journal:  Open Heart       Date:  2019-05-21

3.  Higher cardiorespiratory fitness predicts long-term survival in patients with heart failure and preserved ejection fraction: the Henry Ford Exercise Testing (FIT) Project.

Authors:  Olusola A Orimoloye; Swetha Kambhampati; Albert J Hicks; Mahmoud Al Rifai; Michael G Silverman; Seamus Whelton; Waqas Qureshi; Jonathan K Ehrman; Steven J Keteyian; Clinton A Brawner; Zeina Dardari; Mouaz H Al-Mallah; Michael J Blaha
Journal:  Arch Med Sci       Date:  2019-03-04       Impact factor: 3.318

4.  Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure.

Authors:  Barry Greenberg; Eric D Peterson; Jeffrey S Berger; François Laliberté; Qi Zhao; Guillaume Germain; Dominique Lejeune; Jennifer W Wu; Patrick Lefebvre; Gregg C Fonarow
Journal:  Clin Cardiol       Date:  2019-01-07       Impact factor: 2.882

5.  Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis.

Authors:  Selina Hein; Jennifer Furkel; Maximilian Knoll; Fabian Aus dem Siepen; Stefan Schönland; Ute Hegenbart; Hugo A Katus; Arnt V Kristen; Mathias H Konstandin
Journal:  Clin Res Cardiol       Date:  2021-01-22       Impact factor: 5.460

Review 6.  Cardiotoxicity of Anticancer Therapeutics.

Authors:  Jerry Dong; Hong Chen
Journal:  Front Cardiovasc Med       Date:  2018-02-07

7.  Effect of exercise therapy on established and emerging circulating biomarkers in patients with heart failure: a systematic review and meta-analysis.

Authors:  Melissa J Pearson; Nicola King; Neil A Smart
Journal:  Open Heart       Date:  2018-07-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.